Request Demo
Last update 25 Oct 2025
HS-10370
Last update 25 Oct 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms HS 10370, HS-10370, HS10370 |
Target |
Action inhibitors |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
7
Clinical Trials associated with HS-10370NCT06963502
A Phase Ib Study Evaluating the Safety, Tolerability , Pharmacokinetics，Activity and Immunogenicity of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
NCT06594874
A Phase Ib Study Evaluating the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
CTR20243216
HS-10370联合治疗在晚期实体瘤患者中的安全性、耐受性、药代动力学和有效性的Ib期临床研究
[Translation] A Phase Ib clinical study of the safety, tolerability, pharmacokinetics and efficacy of HS-10370 combination therapy in patients with advanced solid tumors
100 Clinical Results associated with HS-10370
Login to view more data
100 Translational Medicine associated with HS-10370
Login to view more data
100 Patents (Medical) associated with HS-10370
Login to view more data
100 Deals associated with HS-10370
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 03 Jun 2022 | |
| Colorectal Cancer | Phase 1 | China | 30 May 2025 | |
| KRAS G12C mutation Solid Tumors | Phase 1 | China | 31 Oct 2024 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 1 | China | 09 Oct 2024 | |
| KRAS G12C mutant Non-small Cell Lung Cancer | Phase 1 | China | 27 May 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | KRAS G12C mutation Solid Tumors KRAS G12C mutation | 63 | lmhqmlianz(ervhqxwvbd) = 28.6% myzkxiohyg (cliapcwurb ) View more | Positive | 29 Apr 2025 | ||
Phase 1 | KRAS G12C mutation Solid Tumors KRAS G12C | 55 | komhyjilia(syzbllhxhq) = qwahfbsero sglwlowmpz (ovgfbystnt ) View more | Positive | 05 Apr 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free